Search
The launch of B·R·A·H·M·S MR-proADM II KRYPTOR supports the long-term sustainability of the KRYPTOR portfolio. While the previous MR-proADM assay was based on polyclonal antibodies and delivered consistent performance, MR-proADM II was redeveloped with monoclonal antibodies to help provide enhanced specificity, analytical robustness, and scalable manufacturing without compromising established assay consistency.
Method comparison:
To demonstrate alignment and assess comparability between the B·R·A·H·M·S MR-proADM II KRYPTOR assay (y) with a commercially available B·R·A·H·M·S MR-proADM KRYPTOR assay (x) two comparisons were made using clinical samples of both.
An external study done in a polyclinic compared the B·R·A·H·M·S MR-proADM II KRYPTOR assay (y) with B·R·A·H·M·S MR-proADM KRYPTOR assay (x) reported the following correlation [nmol/L]:
Equation: y= 1.01 x + 0.09
Correlation: r = 0.98
Regression Analysis: Passing/Bablok
Comparative Assays: B·R·A·H·M·S MR-proADM KRYPTOR
Number of samples measured: 156 (76 fresh and 80 frozen EDTA plasma samples) in the range 0,37 nmol/L and 9.9 nmol/L.
Samples were collected in patients with suspected infection and other diseases related with the intended use of the test.
Agreements between both methods were calculated for the cut-offs 0.87, 1.5 and 2.25 nmol/L. Positive percent agreements were 98.8%, 98.4% and 97.7%, respectively. Negative percent agreements were 91.4%, 98.9% and 97.3, respectively
Figure: external Method Comparison Passing-Bablok Regression
In-house method comparison passing-bablok regression
Another study was done in house compared the B·R·A·H·M·S MR-proADM II KRYPTOR assay (y) with B·R·A·H·M·S MR-proADM KRYPTOR assay (x) reported the following correlation [nmol/L]:
Equation: y= 0.986 x + 0.07918
Correlation: r = 0.99
Regression Analysis: Passing/Bablok
Comparative Assays: B·R·A·H·M·S MR-proADM KRYPTOR
Number of samples measured: 150
Agreements between both methods were calculated for the cut-offs 0.87, 1.5 and 2.25 nmol/L. Positive percent agreements were 100%, 100% and 98.6%, respectively. Negative percent agreements were 96.2%, 97.1% and 97.9%, respectively.
Figure: in-house Method Comparison Passing-Bablok Regression
Strong Analytical Agreement Supporting Confident Assay Transition
The B·R·A·H·M·S MR-proADM II KRYPTOR assay demonstrates strong analytical correlation with the established B·R·A·H·M·S MR-proADM KRYPTOR assay.
Correlation coefficients of r = 0.98 and r = 0.99, with regression slopes approaching unity, confirm a high degree of analytical agreement and result comparability.
Across more than 300 clinical samples, including both fresh and frozen specimens, external and in-house studies consistently demonstrate analytical performance and alignment. The data support continuity of results and enables laboratories to transition with confidence while maintaining clinical reliability.
Advance your MR-proADM testing with demonstrated continuity and performance.
Discover how the B·R·A·H·M·S MR-proADM II KRYPTOR assay can support your laboratory’s clinical decision-making and performance
Let’s move diagnostics forward — together.
Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.
© 2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S MR-proADM is a registered trademark of B·R·A·H·M·S GmbH.
Nobel Prize is a registered trademark of the Nobel Foundation. Other product names in this document are used for identification purposes; they may be trademarks and/or registered trademarks of their respective companies.
TRACE and KRYPTOR are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific.
View patents and patent marking.